Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and... Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. 詳細を表示
Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic...
PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted...
Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.39 | -12.7450980392 | 3.06 | 3.2 | 2.6 | 74479 | 2.86677404 | CS |
4 | -1.89 | -41.4473684211 | 4.56 | 10 | 2.5 | 1346049 | 3.68683919 | CS |
12 | -3.81 | -58.7962962963 | 6.48 | 10 | 2.5 | 493020 | 3.92130874 | CS |
26 | -10.37 | -79.5245398773 | 13.04 | 16 | 2.5 | 294417 | 4.52796113 | CS |
52 | -8.85 | -76.8229166667 | 11.52 | 18.7192 | 2.5 | 185810 | 6.5700133 | CS |
156 | -1456.5108 | -99.8170206187 | 1459.1808 | 1649.4016 | 2.5 | 1905566 | 596.87746217 | CS |
260 | -15323.41 | -99.9825787155 | 15326.08 | 39916.8 | 2.5 | 2312891 | 2600.82030704 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約